Cantel Medical Corp. Posts Double-Digit Growth Across the Board
On Thursday, Cantel Medical (NYSE: CMD) reported revenue and earnings for its second fiscal quarter, posting solid double-digit growth on both the revenue and earnings line.
Cantel Medical results: The raw numbers
|
Metric |
Q2 2017 |
Q2 2016 |
Year-Over-Year Change |
|---|---|---|---|
|
Revenue |
$184.8 million |
$158.3 million |
16.8% |
|
Income from operations |
$28.6 million |
$22.3 million |
17.3% |
|
Earnings per share |
$0.43 |
$0.37 |
16.2% |
Data source: Cantel Medical.
What happened with Cantel Medical this quarter?
- Most of Cantel's revenue growth -- 12.1 percentage points -- came from organic growth, with 5.8 percentage points coming from acquisitions. If you're doing the math at home, that's more than the overall 16.8% year-over-year growth due to a negative 1.1% impact from changes in currency.
- Cantel's heathcare disposal segment was the highest-growing segment with sales up 35.6% year over year. Most of that growth came from the acquisition of Accutron; organic growth for the segment was up just 6.5% year over year.
- Meanwhile, Cantel's endoscopy segment is getting it done internally with organic growth of 16%.
- Rounding out the segments, growth in sales in the water purification and filtration segment was below the company average, but still a healthy 9.6% year over year. The company is constrained in how fast it can build and install the capital equipment with the backlog reaching record levels, suggesting there should be solid growth in the segment for the rest of the fiscal year.
- Gross margins increased 220 basis points, to 47.9%, partially due to the selling of more higher-margin products, but improving efficiency also contributed to a higher fraction of the revenue falling to the income line.
- Cantel continues to pay down debt -- $12 million in the most recent quarter -- that was taken on during recent acquisitions of Accutron and its Canadian distributor.
Image source: Getty Images.
What management had to say
Cantel continues eliminating international distributors and selling directly to customers.Jorgen Hansen, Cantel's president and CEO, described this in detail:
On the potential for more acquisitions, Seth Yellin, executive VP of strategy and corporate development, stressed that Cantel is actively looking:
Looking forward
Cantel continues to make progress on its way to its goal of doubling sales and profits between 2016 and 2021. Management noted that the second half of the 2016 fiscal year was fairly strong, making for a hard year-over-year comparison for the upcoming quarters, but didn't provide guidance. Ultimately, hitting the revenue and earnings goal will likely require some of those aforementioned acquisitions to come to fruition.
10 stocks we like better than Cantel MedicalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Cantel Medical wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Cantel Medical. The Motley Fool has a disclosure policy.